← Back to Screener
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Price$31.83
Favorite Metrics
Price vs S&P 500 (26W)35.81%
Price vs S&P 500 (4W)-5.36%
Market Capitalization$109.13B
P/E Ratio (Annual)25.76x
All Metrics
P/CF (Annual)22.04x
Book Value / Share (Quarterly)$6.88
P/TBV (Annual)9.31x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)4.96%
Cash Flow / Share (Quarterly)$1.00
Price vs S&P 500 (YTD)-8.23%
Gross Margin (TTM)52.72%
Net Profit Margin (TTM)8.17%
EPS (TTM)$1.21
10-Day Avg Trading Volume0.90M
EPS Excl Extra (TTM)$1.21
Revenue Growth (5Y)0.71%
EPS (Annual)$1.21
ROI (Annual)5.71%
Gross Margin (Annual)52.87%
Net Profit Margin (5Y Avg)-3.80%
Cash / Share (Quarterly)$3.09
P/E Basic Excl Extra (TTM)25.77x
Revenue Growth QoQ (YoY)11.40%
P/E Normalized (Annual)25.76x
ROA (Last FY)3.46%
Revenue Growth TTM (YoY)4.32%
EBITD / Share (TTM)$2.71
ROE (5Y Avg)-9.48%
Operating Margin (TTM)12.49%
Cash Flow / Share (Annual)$1.00
P/B Ratio4.59x
P/B Ratio (Quarterly)4.86x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)2.87x
Net Interest Coverage (TTM)2.41x
ROA (TTM)3.54%
EV / EBITDA (TTM)15.79x
EPS Incl Extra (Annual)$1.21
Current Ratio (Annual)1.04x
Quick Ratio (Quarterly)0.72x
3-Month Avg Trading Volume1.45M
52-Week Price Return11.38%
EV / Free Cash Flow (Annual)43.20x
P/E Incl Extra (TTM)25.77x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$3.59
P/S Ratio (Annual)2.11x
Asset Turnover (Annual)0.42x
52-Week High$11350.00
Operating Margin (5Y Avg)1.90%
EPS Excl Extra (Annual)$1.21
CapEx CAGR (5Y)-2.82%
Tangible BV CAGR (5Y)30.21%
26-Week Price Return44.56%
Quick Ratio (Annual)0.72x
13-Week Price Return-4.66%
Total Debt / Equity (Annual)2.12x
Current Ratio (Quarterly)1.04x
Enterprise Value$49,591.421
Revenue / Share Growth (5Y)-0.50%
Asset Turnover (TTM)0.43x
Book Value / Share Growth (5Y)-5.53%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.63x
Pretax Margin (Annual)7.09%
Cash / Share (Annual)$3.09
3-Month Return Std Dev33.63%
Gross Margin (5Y Avg)50.54%
Net Income / Employee (TTM)$0
EBITDA Interim CAGR (5Y)13.27%
ROE (Last FY)17.84%
Net Interest Coverage (Annual)2.34x
EPS Basic Excl Extra (Annual)$1.21
P/FCF (TTM)26.33x
Receivables Turnover (TTM)5.10x
EV / Free Cash Flow (TTM)43.20x
Total Debt / Equity (Quarterly)2.12x
EPS Incl Extra (TTM)$1.21
Receivables Turnover (Annual)5.10x
ROI (TTM)5.89%
P/S Ratio (TTM)2.11x
Pretax Margin (5Y Avg)-4.33%
Revenue / Share (Annual)$14.84
Tangible BV / Share (Annual)$3.59
Forward P/E11.64x
Free OCF CAGR (5Y)12.47%
Price vs S&P 500 (52W)17.87%
P/E Ratio (TTM)25.77x
Year-to-Date Return-4.28%
5-Day Price Return1.13%
EPS Normalized (Annual)$1.21
ROA (5Y Avg)-1.34%
Net Profit Margin (Annual)8.18%
Month-to-Date Return4.54%
Cash Flow / Share (TTM)$-3.69
EBITD / Share (Annual)$2.66
Operating Margin (Annual)12.50%
LT Debt / Equity (Annual)1.89x
P/CF (TTM)22.04x
ROI (5Y Avg)-2.12%
P/E Excl Extra (TTM)25.77x
LT Debt / Equity (Quarterly)1.89x
EPS Basic Excl Extra (TTM)$1.21
P/TBV (Quarterly)9.31x
P/B Ratio (Annual)4.86x
Inventory Turnover (TTM)2.64x
Pretax Margin (TTM)7.09%
Book Value / Share (Annual)$6.88
Price vs S&P 500 (13W)-7.52%
Beta0.38x
P/FCF (Annual)31.66x
Revenue / Share (TTM)$14.73
ROE (TTM)19.97%
52-Week Low$4865.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TEVATeva Pharmaceutical Industries Limited American Depositary Shares | 2.11x | 4.32% | 52.72% | — | $31.83 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.71 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Teva is the world's leading generic pharmaceutical manufacturer, with approximately half its revenue derived from North America where it captures a high single-digit percentage of US generic prescriptions. Beyond generics, the Israel-based company operates a specialty portfolio including innovative medicines and biosimilars across central nervous system, respiratory, and oncology therapeutic areas. Teva also generates revenue through active pharmaceutical ingredients, contract manufacturing, and Anda, its US-based generic and specialty drug distributor.